Active-targeted candidates like MM-302 (phase II, HER2-targeted doxorubicin liposomes) reported partial responses in 11% of anthracycline-pretreated breast cancer patients, with a median PFS of 7.6 months versus 3.5 months historical controls, though immunogenicity limited dosing [60]. Here, ERBB2 is linked to breast carcinoma.